JDRF and Lilly partner to fund research to identify beta cell ...(ing to a cure said Arnold W. Donald Pres...),Health

Date:11/14/2007

ing to a cure, said Arnold W. Donald, President and Chief Executive Officer of JDRF. As the field of diabetes research moves from purely discovery research to the development of therapeutic cures and treatments, biomarkers will play a key role in increasing the pace of progress, and providing real benefits to people with diabetes. Lillys grant to support beta cell mass and function research will play an important role in these efforts.

According to Dr. Paul Burn, Senior Vice President, Research, at JDRF, there are few current biomarkers for type 1 diabetes research and treatment. Biomarkers would be a powerful research tool in indicating the onset, status, and stage of diabetes; in predicting and monitoring a patients clinical response to treatments developed as part of research funded by JDRF, Lilly, and others; and in accelerating the development of therapeutics by enabling researchers to rapidly assess the clinical outcomes of promising drug candidates.

Biomarkers and the comprehensive information they can provide researchers are imperative to the progress of diabetes research, Dr. Burn said. This project can rapidly advance the pace of scientific discovery and therapeutic developments for type 1 diabetes patients along multiple research pathways to finding a cure. Lilly is making a tremendous contribution to science that could, in turn, significantly improve the lives and outlooks of millions.

Lillys highest mission is to improve the lives of the people we serve and there is no group of patients with whom we have a longer and deeper relationship than people with diabetes, said Dr. John C. Lechleiter, Lillys President and Chief Operating Officer. Until theres a cure for diabetes, its imperative that we continue searching for ways to improve treatment and solutions for managing this condition and its devastating complications. This research by JDRF could provide breakthroughs that would move the treatment of diabetes forward
'/>"/>

Contact: Susan Sherman ssherman@jdrf.org 212-479-7510 Juvenile Diabetes Research Foundation International Source:Eurekalert

0 GOOD

Page: 1 2 3
Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division
3. Lauren Marangell, M.D. to Join Lilly; Internationally Recognized Expert in Depression Joins as Distinguished Lilly Scholar
4. Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
5. Lillys CEO Calls for Reform of Nations Drug Safety System
6. Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
7. Lilly Grant to VA Will Enhance Services for Returning Combat Veterans
8. Lilly Delivers Strong Third-Quarter Results
9. Lilly and MacroGenics Announce Licensing and Collaboration Agreement
10. Eli Lilly and Company Aids California Recovery Effort
11. Eli Lilly and Company Announces 2007 Lilly Reintegration Awards Recipients